Stock listing
Hanover:42Z Revolution Medicines, Inc. Aktie
German listing (Hanover) of Revolution Medicines, Inc. · home listing NASDAQ:RVMD
Follow Revolution Medicines, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RVMD
$182.15 USD +4.19 (+2.4%)
Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RVMD
- Day range
- $177.95 – $183.87 USDOct 19, 2026
- Volume
- 1.98M sharesOct 19, 2026
- Market value
- $39.04B USDAt the close on Oct 19, 2026 · price × 214.3M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RVMD · Home | $182.15 USD | +4.19 (+2.4%) | 1,978,316 | $179.84 | $183.87 | $177.95 | $177.96 | Close on Oct 19, 2026 |
| Frankfurt:42Z | €159.75 EUR | 0.00 (0.0%) | 103 | €159.75 | €164.55 | €159.75 | €159.75 | Close on Oct 19, 2026 |
Daily closes
Last 3 months, Jul 20, 2026 – Oct 19, 2026 · NASDAQ:RVMD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $182.15 | +4.19 | +2.4% | $179.84 | $183.87 | $177.95 | 1,978,316 | |
| $177.96 | -11.30 | -6.0% | $189.68 | $189.68 | $175.91 | 2,973,285 | |
| $189.26 | -4.26 | -2.2% | $193.31 | $195.94 | $189.14 | 1,568,321 | |
| $193.52 | +5.08 | +2.7% | $186.84 | $197.00 | $185.88 | 2,463,046 | |
| $188.44 | -5.51 | -2.8% | $191.57 | $193.61 | $187.14 | 2,939,058 | |
| $193.95 | +4.19 | +2.2% | $187.79 | $194.26 | $184.76 | 1,667,435 | |
| $189.76 | +1.64 | +0.9% | $186.01 | $193.50 | $184.37 | 2,210,434 | |
| $188.12 | -12.75 | -6.3% | $198.51 | $199.64 | $180.49 | 4,857,591 | |
| $200.87 | +1.00 | +0.5% | $198.18 | $203.50 | $196.25 | 1,184,900 | |
| $199.87 | -7.81 | -3.8% | $208.57 | $208.57 | $195.00 | 1,631,600 | |
| $207.68 | +1.04 | +0.5% | $207.68 | $210.27 | $201.83 | 1,424,300 | |
| $206.64 | +0.75 | +0.4% | $205.89 | $208.82 | $204.07 | 1,570,300 | |
| $205.89 | +0.63 | +0.3% | $204.00 | $210.88 | $203.26 | 2,103,900 | |
| $205.26 | +0.78 | +0.4% | $205.48 | $209.79 | $203.00 | 1,844,700 | |
| $204.48 | +2.74 | +1.4% | $201.41 | $204.96 | $200.00 | 1,721,900 | |
| $201.74 | -3.23 | -1.6% | $203.97 | $204.98 | $200.98 | 1,814,500 | |
| $204.97 | +5.11 | +2.6% | $200.54 | $211.51 | $197.97 | 2,520,300 | |
| $199.86 | +9.12 | +4.8% | $190.15 | $201.28 | $189.84 | 4,061,800 | |
| $190.74 | -2.12 | -1.1% | $193.30 | $196.71 | $189.05 | 2,124,800 | |
| $192.86 | +0.10 | +0.1% | $191.56 | $195.28 | $191.22 | 1,881,800 | |
| $192.76 | +1.81 | +0.9% | $192.61 | $194.93 | $190.57 | 1,888,600 | |
| $190.95 | -5.99 | -3.0% | $197.00 | $197.10 | $188.18 | 5,938,100 | |
| $196.94 | +1.02 | +0.5% | $198.53 | $202.02 | $194.80 | 1,820,800 | |
| $195.92 | -8.94 | -4.4% | $204.84 | $205.15 | $193.58 | 3,036,700 | |
| $204.86 | -0.25 | -0.1% | $206.98 | $207.00 | $200.24 | 1,268,500 | |
| $205.11 | +1.34 | +0.7% | $203.50 | $206.55 | $200.17 | 1,273,600 | |
| $203.77 | +0.42 | +0.2% | $204.98 | $206.36 | $197.81 | 1,378,500 | |
| $203.35 | -4.33 | -2.1% | $205.85 | $207.84 | $202.59 | 810,400 | |
| $207.68 | +0.36 | +0.2% | $206.01 | $213.00 | $204.46 | 1,227,000 | |
| $207.32 | -2.70 | -1.3% | $208.07 | $213.00 | $206.30 | 2,390,100 | |
| $210.02 | -0.85 | -0.4% | $209.01 | $211.75 | $207.48 | 884,500 | |
| $210.87 | +1.64 | +0.8% | $207.04 | $212.06 | $207.04 | 1,119,100 | |
| $209.23 | -0.64 | -0.3% | $211.36 | $211.91 | $205.22 | 1,329,600 | |
| $209.87 | +4.30 | +2.1% | $204.64 | $210.26 | $202.54 | 1,830,200 | |
| $205.57 | -2.31 | -1.1% | $205.14 | $207.02 | $200.53 | 2,268,800 | |
| $207.88 | -13.27 | -6.0% | $221.50 | $221.50 | $205.82 | 2,005,000 | |
| $221.15 | +5.71 | +2.7% | $219.48 | $224.31 | $216.13 | 3,359,200 | |
| $215.44 | +4.06 | +1.9% | $209.32 | $218.30 | $198.91 | 3,524,100 | |
| $211.38 | -0.20 | -0.1% | $214.27 | $216.24 | $209.63 | 1,377,300 | |
| $211.58 | +2.12 | +1.0% | $209.46 | $211.95 | $205.39 | 1,598,000 | |
| $209.46 | -2.275 | -1.1% | $212.06 | $212.74 | $206.75 | 2,124,000 | |
| $211.74 | -2.925 | -1.4% | $212.26 | $213.74 | $208.02 | 1,563,400 | |
| $214.66 | -1.34 | -0.6% | $218.84 | $220.34 | $212.25 | 1,307,800 | |
| $216.00 | +4.00 | +1.9% | $209.15 | $216.72 | $209.09 | 1,651,900 | |
| $212.00 | +8.29 | +4.1% | $204.02 | $215.97 | $203.18 | 2,440,300 | |
| $203.71 | +1.71 | +0.8% | $201.50 | $204.00 | $198.89 | 784,200 | |
| $202.00 | -3.26 | -1.6% | $206.85 | $206.85 | $201.02 | 986,800 | |
| $205.26 | -0.29 | -0.1% | $206.99 | $208.49 | $203.75 | 1,175,800 | |
| $205.55 | -1.42 | -0.7% | $207.26 | $208.25 | $202.01 | 1,681,002 | |
| $206.97 | +1.82 | +0.9% | $205.70 | $208.76 | $203.70 | 2,101,103 | |
| $205.15 | +7.34 | +3.7% | $200.82 | $205.90 | $196.49 | 1,665,200 | |
| $197.81 | +0.51 | +0.3% | $197.72 | $203.00 | $195.42 | 1,747,600 | |
| $197.30 | +3.84 | +2.0% | $194.05 | $198.30 | $192.56 | 1,952,900 | |
| $193.46 | +11.01 | +6.0% | $183.53 | $194.08 | $181.02 | 1,614,200 | |
| $182.45 | -5.08 | -2.7% | $184.43 | $186.25 | $180.14 | 1,827,100 | |
| $187.53 | -4.64 | -2.4% | $192.00 | $192.00 | $186.15 | 1,491,800 | |
| $192.17 | +11.25 | +6.2% | $183.72 | $192.77 | $182.00 | 1,806,600 | |
| $180.92 | -2.94 | -1.6% | $184.21 | $185.04 | $178.07 | 2,298,900 | |
| $183.86 | -4.21 | -2.2% | $186.60 | $188.68 | $181.49 | 2,401,400 | |
| $188.07 | -1.16 | -0.6% | $188.91 | $194.56 | $186.98 | 1,425,700 | |
| $189.23 | +0.48 | +0.3% | $189.23 | $190.50 | $185.89 | 1,287,900 | |
| $188.75 | +5.72 | +3.1% | $182.61 | $193.53 | $180.00 | 2,283,200 | |
| $183.03 | -0.26 | -0.1% | $180.66 | $185.40 | $180.11 | 888,600 | |
| $183.29 | +2.90 | +1.6% | $181.25 | $184.25 | $179.39 | 2,299,800 | |
| $180.39 | -5.77 | -3.1% | $186.64 | $189.85 | $180.16 | 2,538,600 |
- Ticker
- Hanover:42Z
- Asset type
- Stock
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Oct 20, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
Latest earnings call · Aug 5, 2026
Revolution Medicines (NASDAQ:RVMD) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Aug 26, 2026
Investor Presentation (August 2026)
Investor deck · 33 slides
Calls
Replays
Revolution Medicines (NASDAQ:RVMD) Q2 2026 Earnings Call
Wed, Aug 05, 2026 · 4:30 PM ET
Watch TranscriptRevolution Medicines (NASDAQ:RVMD) Q1 2026 Earnings Call
Wed, May 06, 2026 · 4:30 PM ET
Watch TranscriptRevolution Medicines (NASDAQ:RVMD) Q4 2025 Earnings Call
Wed, Feb 25, 2026 · 4:30 PM ET
Watch Transcript
Latest news
Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Oct 15, 2026
Closed $189.26 (-2.2%) on Oct 15, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Oct 5, 2026
Closed $207.68 (+0.5%) on Oct 5, 2026
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Sep 14, 2026
Closed $204.86 (-0.1%) on Sep 15, 2026
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Sep 2, 2026
Closed $210.87 (+0.8%) on Sep 3, 2026
U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Aug 27, 2026
Closed $221.15 (+2.7%) on Aug 27, 2026
Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration
Aug 11, 2026
Closed $205.55 (-0.7%) on Aug 11, 2026
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Aug 5, 2026
Closed $197.81 (+0.3%) on Aug 6, 2026
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
Jul 29, 2026
Closed $192.17 (+6.2%) on Jul 30, 2026
Decks
Investor Presentation (August 2026)
Investor deck · 33 slides · Aug 26, 2026
Investor Presentation (August 2026)
Investor deck · 99 slides · August 2026
Technical Presentation (July 2026)
Technical · 15 slides · July 2026
AACR 2026
Conference · 15 slides · April 2026
Revolution Medicines, Inc. on 6ix
- News releases
- 46 in the last 12 months · 168 in all · newest Oct 20, 2026 · oldest 2020
- Calls
- 21 calls with a replay · 21 with a transcript · latest Aug 5, 2026
- Decks
- 16 decks · latest Aug 26, 2026
Where Revolution Medicines, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RVMD · Home listing | NASDAQ | United States | USD |
| gettex:42Z | gettex | Germany | EUR |
| LS Exchange:A2PYWG | LS Exchange | Germany | EUR |
| Milan:1RVMD | Milan | Italy | EUR |
| Tradegate:42Z | Tradegate | Germany | EUR |
| BX Swiss:RVMD | BX Swiss | Switzerland | CHF |
| BOATS:RVMD | BOATS | United States | USD |
| Lang & Schwarz:A2PYWG | Lang & Schwarz | Germany | EUR |
| BMV:RVMD | BMV | Mexico | MXN |
| Dusseldorf:42Z | Dusseldorf | Germany | EUR |
| Frankfurt:42Z | Frankfurt | Germany | EUR |
| Hamburg:42Z | Hamburg | Germany | EUR |
| Munich:42Z | Munich | Germany | EUR |
| Stuttgart:42Z | Stuttgart | Germany | EUR |
| BIVA:RVMD | BIVA | Mexico | MXN |
| Hanover:42Z · This page | Hanover | Germany | EUR |
| Xetra:42Z | Xetra | Germany | EUR |
Log in to ask 6ix AI your own questions about Revolution Medicines, Inc.